UroGen Pharma Ltd. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
UroGen Pharma Ltd. (URGN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $29.89 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-02
- UroGen Pharma Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $29.89M, a 19.62% increase from fiscal 2024.
- UroGen Pharma Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $24.99M, a 78.94% increase from fiscal 2023.
- UroGen Pharma Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $13.96M, a 51.81% decline from fiscal 2022.
- UroGen Pharma Ltd. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $28.98M, a 22.51% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $29.89M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $24.99M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $13.96M 10-K · filed 2025-03-10 | |
| 2022-12-31 | $28.98M 10-K · filed 2024-03-14 | |
| 2021-12-31 | $23.66M 10-K · filed 2023-03-24 | |
| 2020-12-31 | $26.37M 10-K · filed 2022-03-21 | -$26.37M 10-K · filed 2021-03-18 |
| 2019-12-31 | -$22.34M 10-K · filed 2021-03-18 | |
| 2018-12-31 | -$16.52M 10-K · filed 2020-03-02 | |
| 2017-12-31 | -$7.57M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $341.00K 10-K · filed 2019-02-28 | |
| 2015-12-31 | -$1.95M 20-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |